On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid

  title={On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid},
  author={Urpo K. Rinne and V J Sonninen and Markku T. Hyypp{\"a}},
Nachweis des stark herabgesetzten Säuregehalts der Homovanillinsäure und der 5-Hydroxy-indolessigsäure im Liquor cerebrospinalis von Parkinsonkranken im Vergleich mit normalen Versuchspersonen. Die Amantadin-Therapie hingegen ergab keine bedeutenden veränderungen und der Gehalt von Dopamin, Noradrenalin und Homovanillinsäure im Gehirn der behandelten Parkinsonpatienten entsprach auch den Werten der übrigen Parkinsonkranken. Ausserdem hatte Amantadin keinen Einfluss auf den endogenen Gehalt… Expand
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats
Nachweis, dass Amantadin-HCl die Aktivität der K−Na-ATPase im Hirnstamm von Ratten erhöht, wird die Veränderung der Membranpermeabilität verantwortlich gemacht. Expand
Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes
The locomotor hyperactivity and the circling movements after amantadine hydrochloride may result from the inhibition of recurrent nigro striatal (dopaminergic) fibers influenced by the increased GABA activity in the substantia nigra, thereby causing disinhibition of the pallidar structures for locomotor activity. Expand
Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
Considering amantadine’s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Expand


The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates
Preliminary experiments have been performed on the possibility that amantadine will inhibit the uptake of dopamine and noradrenaline by this process, and the increase in radioactivity in the supernatant, caused by passive diffusion of the amine, rapidly reached a maximum. Expand
Amantadine-Dopamine Interaction: Possible Mode of Action in Parkinsonism
Intravenous doses of amantadine hydrochloride, an antiviral drug, as small as 0.08 milligram per kilogram may release dopamine and other catecholamines from neuronal storage sites in dogs primed withExpand
In‐Vivo Decarboxylation of α‐Methyl DOPA and α‐Methyl Metatyrosine
α-Methyl DOPA (DOPA = 3,4-dihydroxyphenylalanine) and α-methyl metatyrosine were injected to mice (400 mg/kg intraperitoneally). The former amino acid was also injected to rabbits (200 mg/kgExpand
Drug-induced changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus.
The effects of reserpine and imipramine on the concentration of indolyl compounds bearing an OR group in position 5 in the cerebrospinal fluid and the caudate nucleus of the dog have been studied. Expand
Rapid method for the determination of 5‐hydroxytryptamine and 5‐hydroxyindoleacetic acid in small regions of rat brain
A rapid and sensitive method for measuring 5‐hydroxytryptamine and 5‐hydroxyindoleacetic acid, using o‐phthalaldehyde and L‐cysteine, is presented, enabling both compounds to be measured in smallExpand
A method for the determination of serotonin and norepinephrine in discrete areas of rat brain.
A method for the determination of both serotonin (5HT) and norepinephrine (NE) in small samples of brain is described, applicable to as little as 50 mg of brain tissue. Expand
Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.
Amantadine pretreatment increased both 3 H-DA synthesis and release and the drug effect on striatal dopamine terminals is discussed with respect to its utilization in human Parkinsonism. Expand
Amantadine in parkinsonism.
Abstract A controlled trial of amantadine hydrochloride 100 mg. b.d. in seventeen patients with parkinsonism showed a small beneficial effect on physical signs but no significant effect on functionalExpand
Amantadine in the treatment of Parkinson's disease.
Sixty-six percent of a group of 163 patients with Parkinson's disease exhibited subjective or objective improvement of their akinesia, rigidity, and tremor while receiving amantadine hydrochloride.Expand
A double‐blind control trial of amantadine hydrochloride in a dosage of 200 mg per day, and placebo, confirms the results of previous studies, which showed that the drug is a well‐tolerated drug and has a beneficial effect of varying degree on the disease. Expand